Market Overview:Atezolizumab is a monoclonal antibody developed by Roche for the treatment of various types of cancer including lung cancer, bladder cancer, Hodgkin's lymphoma and triple-negative breast cancer. It blocks the interaction between PD-L1 and PD-1 receptors, enhancing the anti-tumor activity of T-cells. Atezolizumab is administered through intravenous injection and is used as a...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian